Immunogenicity of COVID-19 vaccines and levels of SARS-CoV-2 neutralising antibody in the Bruneian population: Protocol for a national longitudinal study
Introduction Neutralising antibodies (NAbs) have been shown to be correlative of immune protection against SARS-CoV-2. We report the protocol for a national longitudinal study to assess and compare the level of NAbs generated in response to COVID-19 vaccines in Brunei Darussalam in adults 2–6 weeks...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2022-12-01
|
| Series: | BMJ Open |
| Online Access: | https://bmjopen.bmj.com/content/12/12/e067020.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850036024673042432 |
|---|---|
| author | Yan Wang Feng Zhu Yuan Wei Lin Naing Justin Wong Hazim Ghani Liyana Ahmad Hanisah Sharif Saifuddien Bagol Mohammad Fathi Alikhan Surita Taib Chee Wah Tan Xin Mei Ong Chin Yee Shim Si Yee Chan Fazean Idris Lin-Fa Wang Anne Catherine Cunningham |
| author_facet | Yan Wang Feng Zhu Yuan Wei Lin Naing Justin Wong Hazim Ghani Liyana Ahmad Hanisah Sharif Saifuddien Bagol Mohammad Fathi Alikhan Surita Taib Chee Wah Tan Xin Mei Ong Chin Yee Shim Si Yee Chan Fazean Idris Lin-Fa Wang Anne Catherine Cunningham |
| author_sort | Yan Wang |
| collection | DOAJ |
| description | Introduction Neutralising antibodies (NAbs) have been shown to be correlative of immune protection against SARS-CoV-2. We report the protocol for a national longitudinal study to assess and compare the level of NAbs generated in response to COVID-19 vaccines in Brunei Darussalam in adults 2–6 weeks post primary series (BBIBP-CorV, AZD1222, or mRNA-1273 vaccines) and their subsequent follow-up after administration of a third (booster-1) dose (BBIBP-CorV, mRNA-1273, or BNT162b2).Methods and analysis Participant data will be extracted and processed from the national electronic health record system (Bru-HIMS) and the national mobile health application (BruHealth) into a research data platform. Eligible adults who have received their primary or booster vaccine will be invited using a stratified random sampling strategy based on age, gender and vaccine type (baseline target population, n=3000; 2–6 weeks post last dose). Blood serum will be isolated, and NAb levels assessed using the cPass surrogate virus neutralisation test. Baseline participants will then be screened for eligibility for subsequent longitudinal analysis. Those who have received a third dose will be followed up at 1, 3, 6, 9 and up to 12 months. NAb levels will be evaluated across the participant population according to vaccine platform/booster type, time since the last dose and correlated with demographic data. The study period is from December 2021 to January 2023 and aims to evaluate how NAb levels wane following a third vaccine dose across different vaccine platforms and determine the impact and rate of breakthrough infections.Ethics and dissemination This study has been approved by the Medical and Ethical Research Committee of Ministry of Health, Brunei Darussalam. Individual NAb test results will be shared with each participant by text message. The findings from this study will help policy-makers in Brunei develop future vaccination strategies and establish regulations across multiple agencies. |
| format | Article |
| id | doaj-art-d170f2132e344b2fb3f3eaca79281a9b |
| institution | DOAJ |
| issn | 2044-6055 |
| language | English |
| publishDate | 2022-12-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | BMJ Open |
| spelling | doaj-art-d170f2132e344b2fb3f3eaca79281a9b2025-08-20T02:57:20ZengBMJ Publishing GroupBMJ Open2044-60552022-12-01121210.1136/bmjopen-2022-067020Immunogenicity of COVID-19 vaccines and levels of SARS-CoV-2 neutralising antibody in the Bruneian population: Protocol for a national longitudinal studyYan Wang0Feng Zhu1Yuan Wei2Lin Naing3Justin Wong4Hazim Ghani5Liyana Ahmad6Hanisah Sharif7Saifuddien Bagol8Mohammad Fathi Alikhan9Surita Taib10Chee Wah Tan11Xin Mei Ong12Chin Yee Shim13Si Yee Chan14Fazean Idris15Lin-Fa Wang16Anne Catherine Cunningham17Department of Medical Science and Strategy Oncology, Innovent Biologics, Inc, Suzhou, ChinaMedicine (Neurology), University of British Columbia, Vancouver, British Columbia, CanadaLonggang District People’s Hospital of Shenzhen & The Third Affiliated Hospital (Provisional) of The Chinese University of Hong Kong, Shenzhen, Guangdong, ChinaPAPRSB Institute of Health Sciences, Universiti Brunei Darussalam, Gadong, Brunei DarussalamPAPRSB Institute of Health Sciences, Universiti Brunei Darussalam, Gadong, Brunei DarussalamPAPRSB Institute of Health Sciences, Universiti Brunei Darussalam, Gadong, Brunei DarussalamPAPRSB Institute of Health Sciences, Universiti Brunei Darussalam, Gadong, Brunei DarussalamPAPRSB Institute of Health Sciences, Universiti Brunei Darussalam, Gadong, Brunei DarussalamDepartment of Laboratory Services, Ministry of Health Brunei Darussalam, Bandar Seri Begawan, Brunei-Muara, Brunei DarussalamEVYD Research Pte Ltd, A Subsidiary of EVYD Technology Limited, SingaporeDepartment of Laboratory Services, Ministry of Health Brunei Darussalam, Bandar Seri Begawan, Brunei-Muara, Brunei DarussalamProgramme in Emerging Infectious Diseases, Duke-NUS Medical School, SingaporeProgramme in Emerging Infectious Diseases, Duke-NUS Medical School, SingaporeEVYD Research Pte Ltd, A Subsidiary of EVYD Technology Limited, SingaporeEVYD Research Pte Ltd, A Subsidiary of EVYD Technology Limited, SingaporePAPRSB Institute of Health Sciences, Universiti Brunei Darussalam, Gadong, Brunei DarussalamProgramme in Emerging Infectious Diseases, Duke-NUS Medical School, SingaporePAPRSB Institute of Health Sciences, Universiti Brunei Darussalam, Gadong, Brunei DarussalamIntroduction Neutralising antibodies (NAbs) have been shown to be correlative of immune protection against SARS-CoV-2. We report the protocol for a national longitudinal study to assess and compare the level of NAbs generated in response to COVID-19 vaccines in Brunei Darussalam in adults 2–6 weeks post primary series (BBIBP-CorV, AZD1222, or mRNA-1273 vaccines) and their subsequent follow-up after administration of a third (booster-1) dose (BBIBP-CorV, mRNA-1273, or BNT162b2).Methods and analysis Participant data will be extracted and processed from the national electronic health record system (Bru-HIMS) and the national mobile health application (BruHealth) into a research data platform. Eligible adults who have received their primary or booster vaccine will be invited using a stratified random sampling strategy based on age, gender and vaccine type (baseline target population, n=3000; 2–6 weeks post last dose). Blood serum will be isolated, and NAb levels assessed using the cPass surrogate virus neutralisation test. Baseline participants will then be screened for eligibility for subsequent longitudinal analysis. Those who have received a third dose will be followed up at 1, 3, 6, 9 and up to 12 months. NAb levels will be evaluated across the participant population according to vaccine platform/booster type, time since the last dose and correlated with demographic data. The study period is from December 2021 to January 2023 and aims to evaluate how NAb levels wane following a third vaccine dose across different vaccine platforms and determine the impact and rate of breakthrough infections.Ethics and dissemination This study has been approved by the Medical and Ethical Research Committee of Ministry of Health, Brunei Darussalam. Individual NAb test results will be shared with each participant by text message. The findings from this study will help policy-makers in Brunei develop future vaccination strategies and establish regulations across multiple agencies.https://bmjopen.bmj.com/content/12/12/e067020.full |
| spellingShingle | Yan Wang Feng Zhu Yuan Wei Lin Naing Justin Wong Hazim Ghani Liyana Ahmad Hanisah Sharif Saifuddien Bagol Mohammad Fathi Alikhan Surita Taib Chee Wah Tan Xin Mei Ong Chin Yee Shim Si Yee Chan Fazean Idris Lin-Fa Wang Anne Catherine Cunningham Immunogenicity of COVID-19 vaccines and levels of SARS-CoV-2 neutralising antibody in the Bruneian population: Protocol for a national longitudinal study BMJ Open |
| title | Immunogenicity of COVID-19 vaccines and levels of SARS-CoV-2 neutralising antibody in the Bruneian population: Protocol for a national longitudinal study |
| title_full | Immunogenicity of COVID-19 vaccines and levels of SARS-CoV-2 neutralising antibody in the Bruneian population: Protocol for a national longitudinal study |
| title_fullStr | Immunogenicity of COVID-19 vaccines and levels of SARS-CoV-2 neutralising antibody in the Bruneian population: Protocol for a national longitudinal study |
| title_full_unstemmed | Immunogenicity of COVID-19 vaccines and levels of SARS-CoV-2 neutralising antibody in the Bruneian population: Protocol for a national longitudinal study |
| title_short | Immunogenicity of COVID-19 vaccines and levels of SARS-CoV-2 neutralising antibody in the Bruneian population: Protocol for a national longitudinal study |
| title_sort | immunogenicity of covid 19 vaccines and levels of sars cov 2 neutralising antibody in the bruneian population protocol for a national longitudinal study |
| url | https://bmjopen.bmj.com/content/12/12/e067020.full |
| work_keys_str_mv | AT yanwang immunogenicityofcovid19vaccinesandlevelsofsarscov2neutralisingantibodyinthebruneianpopulationprotocolforanationallongitudinalstudy AT fengzhu immunogenicityofcovid19vaccinesandlevelsofsarscov2neutralisingantibodyinthebruneianpopulationprotocolforanationallongitudinalstudy AT yuanwei immunogenicityofcovid19vaccinesandlevelsofsarscov2neutralisingantibodyinthebruneianpopulationprotocolforanationallongitudinalstudy AT linnaing immunogenicityofcovid19vaccinesandlevelsofsarscov2neutralisingantibodyinthebruneianpopulationprotocolforanationallongitudinalstudy AT justinwong immunogenicityofcovid19vaccinesandlevelsofsarscov2neutralisingantibodyinthebruneianpopulationprotocolforanationallongitudinalstudy AT hazimghani immunogenicityofcovid19vaccinesandlevelsofsarscov2neutralisingantibodyinthebruneianpopulationprotocolforanationallongitudinalstudy AT liyanaahmad immunogenicityofcovid19vaccinesandlevelsofsarscov2neutralisingantibodyinthebruneianpopulationprotocolforanationallongitudinalstudy AT hanisahsharif immunogenicityofcovid19vaccinesandlevelsofsarscov2neutralisingantibodyinthebruneianpopulationprotocolforanationallongitudinalstudy AT saifuddienbagol immunogenicityofcovid19vaccinesandlevelsofsarscov2neutralisingantibodyinthebruneianpopulationprotocolforanationallongitudinalstudy AT mohammadfathialikhan immunogenicityofcovid19vaccinesandlevelsofsarscov2neutralisingantibodyinthebruneianpopulationprotocolforanationallongitudinalstudy AT suritataib immunogenicityofcovid19vaccinesandlevelsofsarscov2neutralisingantibodyinthebruneianpopulationprotocolforanationallongitudinalstudy AT cheewahtan immunogenicityofcovid19vaccinesandlevelsofsarscov2neutralisingantibodyinthebruneianpopulationprotocolforanationallongitudinalstudy AT xinmeiong immunogenicityofcovid19vaccinesandlevelsofsarscov2neutralisingantibodyinthebruneianpopulationprotocolforanationallongitudinalstudy AT chinyeeshim immunogenicityofcovid19vaccinesandlevelsofsarscov2neutralisingantibodyinthebruneianpopulationprotocolforanationallongitudinalstudy AT siyeechan immunogenicityofcovid19vaccinesandlevelsofsarscov2neutralisingantibodyinthebruneianpopulationprotocolforanationallongitudinalstudy AT fazeanidris immunogenicityofcovid19vaccinesandlevelsofsarscov2neutralisingantibodyinthebruneianpopulationprotocolforanationallongitudinalstudy AT linfawang immunogenicityofcovid19vaccinesandlevelsofsarscov2neutralisingantibodyinthebruneianpopulationprotocolforanationallongitudinalstudy AT annecatherinecunningham immunogenicityofcovid19vaccinesandlevelsofsarscov2neutralisingantibodyinthebruneianpopulationprotocolforanationallongitudinalstudy |